There are currently no clinically accepted tools to objectively assess pain. Clinicians must rely on patients’ subjective assessments, or simply guess when patients can’t communicate.
NOL™ (Nociception level) Index, is the only pain assessment index based on dozens of pain-related physiological parameters and clinically validated as superior to other nociception/pain indicators 1,2.
The PMD-200™ is a pain monitoring device, based on the patented NOL™ technology, the PMD-200 provides objective, non-invasive, and continuous monitoring of the physiological response to pain.
Medasense develops innovative systems and applications to objectively assess the physiological response to pain, providing insight throughout the pain management process for accurate and personalized pain care. Medasense’s innovative technology platform acquires, processes and analyzes dozens of physiological parameters, transforming them into a single index by using artificial intelligence algorithms. The clinically validated technology is superior to existing pain indicators 1,2.
For the full review, please click here
Israeli anesthesiologists are now able to join their European colleagues, who are already using our technology , to optimize and personalize the intraoperative analgesic administration.
This is a significant milestone for Medasense. We are very proud to enter our home market, where our technology was developed!
Read our article written by CEO, Galit Zuckerman-Stark, to learn how an objective approach could help healthcare professionals better assess pain.
To read the full article click here.
The article is taken from Innovations in Pharmaceutical Technology, July 2017, pages 15-17. © Samedan Ltd
Medasense headlines "Anesthesiology News" - the most-read publication by anesthesiologists in the USA
The article reports on clinical trial results previously published in Anesthesiology in 2016, with insightful interviews from lead investigators, Dr. Daniel Sessler (Head of Center of Outcomes Research, Cleveland Clinic, Ohio, USA) and Dr. Ruth Edry (Department of Anesthesiology, Rambam Medical Centre, Haifa, Israel).
* PMD-200TM is CE marked. In the USA: limited by federal law to investigational use only.
- Intraoperative validation of the NOL Index, a non-invasive nociception monitor. Ruth Edry, Vasile Recea, Yuri Dikust, Daniel I. Sessler. Anesthesiology July 2016, Vol.125, 193-203
- Ability of the Nociception Level (NOL), a multiparameter composite of autonomic signals, to detect noxious stimuli during propofol-remifentanil anesthesia. Chris H. Martini, Martijn Boon, Suzanne J. L. Broens, Evelien F. Hekkelman, Lisanne A. Oudhoff, Anna Willemijn Buddeke, Albert Dahan. Anesthesiology Sept. 2015, Vol.123, 524-534
- Institute of Medicine Report from the Committee on Advancing Pain Research, Care, and Education: Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research. The National Academies Press, 2011.